Amgen, Inc. (NASDAQ:AMGN) Director Sells 2,000 Shares

Amgen, Inc. (NASDAQ:AMGN) Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $175.68, for a total value of $351,360.00. Following the transaction, the director now owns 16,219 shares of the company’s stock, valued at approximately $2,849,353.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of AMGN traded up $0.26 during mid-day trading on Friday, reaching $184.28. 3,753,084 shares of the stock traded hands, compared to its average volume of 2,825,205. Amgen, Inc. has a 1 year low of $166.30 and a 1 year high of $210.19. The business has a fifty day simple moving average of $174.89. The firm has a market cap of $112.40 billion, a P/E ratio of 12.80, a price-to-earnings-growth ratio of 2.24 and a beta of 1.14. The company has a current ratio of 2.77, a quick ratio of 2.53 and a debt-to-equity ratio of 2.71.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, April 30th. The medical research company reported $3.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.45 by $0.11. Amgen had a net margin of 34.00% and a return on equity of 71.02%. The company had revenue of $5.56 billion during the quarter, compared to analyst estimates of $5.55 billion. During the same period in the previous year, the business earned $3.47 earnings per share. The firm’s quarterly revenue was up .1% compared to the same quarter last year. Equities analysts anticipate that Amgen, Inc. will post 13.91 EPS for the current fiscal year.

A number of equities analysts have recently weighed in on the company. Mizuho set a $208.00 target price on Amgen and gave the stock a “buy” rating in a research note on Friday, April 12th. Royal Bank of Canada restated a “neutral” rating and issued a $192.00 target price on shares of Amgen in a research note on Tuesday, May 21st. Oppenheimer set a $210.00 target price on Amgen and gave the stock a “buy” rating in a research note on Friday, May 24th. Citigroup upgraded Amgen from a “neutral” rating to a “buy” rating and cut their target price for the stock from $211.00 to $205.00 in a research note on Wednesday, May 22nd. Finally, Credit Suisse Group assumed coverage on Amgen in a research note on Monday, May 20th. They issued an “outperform” rating and a $208.00 target price on the stock. Ten investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $208.35.

A number of large investors have recently made changes to their positions in AMGN. Bangor Savings Bank boosted its position in Amgen by 2.1% during the first quarter. Bangor Savings Bank now owns 2,682 shares of the medical research company’s stock valued at $510,000 after buying an additional 55 shares during the period. LVW Advisors LLC raised its stake in shares of Amgen by 5.7% during the fourth quarter. LVW Advisors LLC now owns 1,119 shares of the medical research company’s stock valued at $218,000 after acquiring an additional 60 shares during the last quarter. Bank OZK raised its stake in shares of Amgen by 0.4% during the first quarter. Bank OZK now owns 16,628 shares of the medical research company’s stock valued at $3,159,000 after acquiring an additional 60 shares during the last quarter. Diversified Trust Co raised its stake in shares of Amgen by 0.4% during the first quarter. Diversified Trust Co now owns 14,856 shares of the medical research company’s stock valued at $2,822,000 after acquiring an additional 60 shares during the last quarter. Finally, First National Bank of Hutchinson raised its stake in shares of Amgen by 2.6% during the fourth quarter. First National Bank of Hutchinson now owns 2,378 shares of the medical research company’s stock valued at $463,000 after acquiring an additional 61 shares during the last quarter. Institutional investors own 77.23% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Article: How is an ETF different from a mutual fund?

Insider Buying and Selling by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.